H.C. Wainwright Maintains Virios Therapeutics(VIRI.US) With Hold Rating, Maintains Target Price $5
Maintaining Hold on Virios Therapeutics Amid Merger and Clinical Development Uncertainties
Virios Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Neutral on Virios Therapeutics, Lowers Price Target to $0.2
Buy Rating for Virios Therapeutics Amid Promising Long COVID Treatment and Legislative Tailwinds
Hold Rating Maintained for Virios Therapeutics Amidst Financial Uncertainty and Pipeline Prospects
Maxim Group Maintains Virios Therapeutics(VIRI.US) With Buy Rating, Maintains Target Price $1
Optimistic Buy Rating for Virios Therapeutics as IMC-2 Advances in Clinical Trials With Promising Phase 2 Results
Virios Therapeutics Analyst Ratings
Maintaining Hold on Virios Therapeutics Amid Financial Strains and Clinical Development Risks
Virios Therapeutics: A Hold Rating With a New Price Target Amidst Clinical and Financial Challenges
No Data
No Data